A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC

Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)

NCT03433703 ·Status: TERMINATED ·Phase: PHASE2

Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)

NCT00946153 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma

NCT06138769 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment

NCT07297654 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma

NCT04642547 ·Status: COMPLETED ·Phase: NA

Real-world Study of Lenalidomide After First-line Treatment Lenvatinib With PD-1 in Advanced HCC

NCT07184424 ·Status: COMPLETED ·Phase: NA

Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC

NCT05842317 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCC

NCT06519721 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA

Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC

NCT05608213 ·Status: RECRUITING ·Phase: PHASE3

Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma

NCT04401800 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy of Lenvatinib in Subjects With HCC Progression After First Line Treatment With Checkpoint Inhibitors

NCT04428437 ·Status: TERMINATED

To Study the Effects of Addition of Mebendazole to Lenvatinib in Cirrhotics With Advanced Hepatocellular Carcinoma.

NCT04443049 ·Status: UNKNOWN ·Phase: NA

Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma

NCT04168944 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma

NCT03418922 ·Status: COMPLETED ·Phase: PHASE1

Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

NCT05103904 ·Status: TERMINATED ·Phase: PHASE2

Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC

NCT05608200 ·Status: RECRUITING ·Phase: PHASE3

Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer

NCT04656249 ·Status: COMPLETED ·Phase: PHASE2

Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma

NCT01545804 ·Status: COMPLETED ·Phase: PHASE2

A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma

NCT04008082 ·Status: COMPLETED

Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC

NCT04443309 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Lenvatinib vs Bevacizumab Plus ICIs and HAIC in Unresectable HCC

NCT06435013 ·Status: COMPLETED

Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous Ablative

NCT05113186 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)

NCT04560751 ·Status: UNKNOWN

Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma

NCT05444478 ·Status: RECRUITING ·Phase: NA

Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma

NCT05312216 ·Status: UNKNOWN ·Phase: PHASE2